Strides Pharma Science Ltd News

Strides sells majority stake in Pivot Path to Ascent Capital-led consortium

Following the completion of the transaction, Pivot Path will be reclassified from a wholly owned subsidiary to an associate company of Strides

Strides Pharma to sell majority stake in Pivot Path for ₹100 crore

Strides Pharma Science Ltd on Saturday announced divestment of majority stake in its wholly-owned arm Pivot Path for Rs 100 crore to a consortium of investors led by Ascent Capital, along with co-investor Vintage. The board of directors of the company, at its meeting held on June 27, 2026, has approved a strategic investment by a consortium led by Ascent Capital, along with co-investor Vintage Classic, in its wholly owned subsidiary, Pivot Path Pvt Ltd (Pivot Path), Strides Pharma Science Ltd , said in a regulatory filing. The proposed transaction comprises the sale of the majority stake by Strides to Ascent Capital and Vintage Classic for an aggregate consideration of Rs 100 crore and the primary infusion of Rs 50 crore into Pivot Path by Ascent Capital to accelerate the next phase of growth, it added. Strides will receive Rs 75 crore at initial closing and Rs 25 crore on the first anniversary of closing, it added. After the transaction, Strides will hold a 19.95 per cent stake in

Strides Pharma Q4FY26 results: Net profit jumps 51% to ₹129 crore

Strides Pharma Science Ltd on Monday reported a 51 per cent rise in consolidated net profit at Rs 129.28 crore for the fourth quarter ended March 31, 2026 driven by a good growth in its main markets excluding the US. The company had posted a profit of Rs 85.62 crore for the year-ago period, Strides Pharma said in a regulatory filing. Revenue from operations in the quarter stood at Rs 1,323.47 crore as compared to Rs 1,190.39 crore in the year-ago period, it added. In the fourth quarter, revenue from main markets excluding the US was up at Rs 645.8 crore as compared to Rs 480 crore in the year-ago period. The US market revenue was at Rs 646.7 crore, down from Rs 651.5 crore in the year-ago period, the company said in an investor presentation. Total expenses in the quarter under review were higher at Rs 1,178.59 crore as compared to Rs 1,071.71 crore in the same period a year ago, the company said. In FY26, consolidated net profit was at Rs 574.52 crore as compared to Rs 3,597.51 cr

Stocks to Watch today: Tata Steel, Tech Mahindra, Varun Bev, Shree Cement

Stocks to Watch today, March 18: Tata Steel, Tech Mahindra, Varun Beverages, Shree Cement, and Aurobindo Pharma are among the top stocks to watch today

Top trading ideas: Buy Thermax, Ipca Labs and one other share, says analyst

Top trading ideas: Aakash Shah of Choice Equity Broking suggests buying these three stocks today; here's why

Strides Pharma jumps 12% on healthy Q3 operational performance

The management said Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets.

Strides Pharma Q3FY26 results: Net profit doubles to ₹208.12 cr

Strides Pharma Science Ltd on Friday reported over two-fold rise in consolidated net profit at Rs 208.12 crore in the third quarter ended December 31, 2025 on the back of robust sales growth and one time income on sale of property. The company had posted a consolidated net profit of Rs 90.04 crore in the corresponding quarter last fiscal, Strides Pharma Science Ltd said in a regulatory filing. Consolidated revenue from operations in the third quarter stood at Rs 1,194.65 crore as against Rs 1,153.67 crore in the year-ago period, it added. Total expenses in the quarter under review were higher at Rs 1,052.7 crore as compared to Rs 1,043.96 crore in the same period a year ago, the company said. The company said during the third quarter it sold its investment property consisting of land and building for a consideration of Rs 112.87 crore and recorded a profit of Rs 102.14 crore as other income. Commenting on the performance, Strides Pharma Science MD & Group CEO, Badree Komandur, ...